#1 Trusted Probiotic Among Therapists
Probiotics for Health Professional
Developed by Wasa Medicals AB in Sweden, ProBion dry tablets were used in recent human clinical study aimed at ascertaining effect of probiotics on gut bacteria in colon cancer patients. It has been found that two tablets of ProBion Clinica a day for an average of 31 days had wiped out a significant amount of cancer associated harmful bacteria and generated a plethora of beneficial bacteria with anti-inflammatory effects. It showed promise in using probiotics to mitigate dysbiosis and improve gut health for cancer prevention. It also showed that ProBion tablets delivered undamaged probiotic bacteria in the large intestines to achieve therapeutic effect. The study was conducted by scientists at the Sahlgrenska University Hospital in Gothenburg. Results published in July 2017 in BMJ Journal, a leading open access platform for scientific papers specialising in gastroenterology.
Wasa Medicals AB, based in Halmstad, Sweden, is a member of the International Probiotic Association (IPA). Led by CEO Lennart Cedgard, MD, the company developed the ProBion dry tablet matrix through collaboration with Swedish doctors and scientists, and has continuously researched probiotic dosage effect for 25 years. Mr Cedgard has over 35 years clinical experience in intestinal microecology and is contributor of papers on probiotics and microbiology to medical journals, dedicated to study innovative use of probiotics for alleviating diseases.
Analysed by independent labs using Flow Cytometric Fluorescence technique with FISH and FC analyses, our probiotics have the viability, bacteria integrity and quality assurance needed for clinical trials
Dysbiosis and Inflammatory Diseases
Detoxification Dysbiosis is linked to inflammatory related diseases
The intestinal microbiota play an important role in the digestion and absorption of food, modulation of the immune system, production of vitamins, protection against pathogens and regulation of hormones that impact diseases. Interaction between the normal microbiota and the human intestinal mucosa is essential for proper intestinal function. An imbalance within the intestinal microbiota (dysbiosis) may be caused by poor diet, infection, or treatment with antibiotics. Dysbiosis will affect cell proliferation in the colon mucosa and may lead to the development of adenomas (precancerous lesions of colon cancer). Intestinal microbial dysbiosis has also been observed in type-2- diabetes. Celiac disease is an inflammatory, autoimmune disease triggered by gluten, although gluten proteins are responsible for the symptoms of celiac disease, gastrointestinal infections may also play a role. Recent data show that the intestinal microbiota of celiac disease patients display a more disturbing bacterial composition than for healthy individuals.
The Way Forward
Scientific Research by Wasa Medicals Dysbiosis is linked to inflammatory related diseases
It is increasingly accepted by the medical community and society at large that intestinal microbiota form an important part of our immune system, and have a profound influence on our state of health or disease. With rising incidences of inflammatory diseases such as colorectal cancer, type-2 diabetes, celiac disease (gluten intolerance) and infertility, the need for prevention, early detection and cost-effective care has never been greater. Having first-hand experience with how probiotics can restore or enhance the balance of our intestinal microbiota, we at Wasa Medicals believe probiotics is the future of medicine. Targeted research is needed to develop a new approach toward disease prevention and the reversing of early stage illnesses. We believe microbiota affect expression of mediators in inflammatory pathways in intestinal cells, and in turn trigger diseases. When treated with probiotics, normal microbiota can be restored and aberrant mechanisms that lead to diseases can be reversed.
